Positive Results From Phase 3 Study Of Avanafil In Erectile Dysfunction Presented At AUA Annual Meeting
VIVUS, Inc. (Nasdaq: VVUS) announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting. The data, "Avanafil for the Treatment of Erectile Dysfunction: Results of a Phase 3, Multi-Center, Randomized, Double Blind, Placebo-Controlled Clinical Trial, " were presented by Irwin Goldstein, MD, clinical professor of surgery, University of California, San Diego and director of sexual medicine at Alvarado Hospital, San Diego, California. The presentation marks the first time these results have been shared with the medical community at a major medical meeting. The REVIVE study met all primary endpoints across the three doses studied by demonstrating statistically significant improvements in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the International Index of Erectile Function (IIEF) score.
Physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center presented their latest research findings at the American Urological Association's Annual Meeting in San Francisco, May 29 to June 3. Dr. Steven Kaplan, a urologist and professor of urology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and Dr. Darracott Vaughan, senior author and professor emeritus of urology at Weill Cornell Medical College, have published data showing that 5-alpha reductase inhibitors (5-ARI), drugs used to control for benign prostatic hypertrophy (BPH), an enlarged prostate, may greatly improve the accuracy of traditional PSA tests for prostate cancer diagnosis. "Taking 5-ARI drugs may eliminate the background noise associated with PSA testing -- canceling out a benign response and leaving only one signal for malignancy, " explains Dr.
Given that it is not clear whether male menopause actually exists, and inconclusive evidence on testosterone's effectiveness in treating it, an article in today's Drug Therapeutics Bulletin (DTB), a BMJ (British Medical Journal) journal, says that the use of synthetic testosterone is questionable. Testosterone levels drop by approximately 1% to 2% annually from the age of 40 years in men, while in women levels of estrogen take a nosedive during the menopause and production stops almost completely. In males, testosterone production does not stop, the DTB says. About 80% of 60 year-old males and half of 80 year-old males still have testosterone levels within the normal range for younger men. The articles states that low levels of testosterone are not an inevitable consequence of ageing.
'Sonic Hedgehog' Helps Regenerate Critical Nerve That Runs Along Prostate, Could Heal Erectile Dysfunction After Surgery
After men have surgery to remove a cancerous prostate gland, up to 80 percent of them will lose the ability to have an erection because of damage to a critical nerve that runs along the prostate. New research from Northwestern University Feinberg School of Medicine shows the damaged nerve can be regenerated more quickly with a protein called sonic hedgehog delivered via a nanofiber gel. The study, done with rats, showed the protein regenerated the damaged nerve twice as fast as it would have regenerated on its own. Speeding up the nerve healing is essential in order to prevent cell death in the penis and to preserve erectile function. "This discovery about sonic hedgehog could be applicable not only to erectile dysfunction after prostate surgery but also when the cavernous nerve is damaged by diabetes, which also causes erectile dysfunction, " said principal investigator Carol Podlasek, assistant professor of urology at Feinberg and a member of the Robert H.
Scientists are reporting development and successful initial tests of a potential new delivery system for the biological signaling agent responsible for the effects of Viagra. It could be used to deliver the substance, called nitric oxide or NO, to treatment conditions ranging from heart disease to skin ulcers and other wounds that fail to heal, according to a report in the Journal of the American Chemical Society. JoĆ o Rocha and colleagues explain that NO acts as an important agent in the body for expanding blood vessels (its role in Viagra and related medicines for erectile dysfunction ), preventing the formation of blood clots, aiding nerve signals, and repairing wounds. NO's multipurpose role makes it an exciting prospect for new drug development, but current NO delivery systems sometimes cause undesirable side effects.